The U.K.’s National Health Service considers patents for diagnostics and genes “unacceptable, unenforceable and detrimental to the delivery of patient services” and is deliberately ignoring them, the U.K.’s Financial Times reported.
At a meeting of the U.K.’s Human Genetics Commission, Michael Hopkins of the Science Policy Research Unit at the University of Sussex said health-care systems throughout Europe have similar policies, according to the Financial Times.
